EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients

被引:25
|
作者
Yang, Shi-Yi [1 ,5 ]
Yang, Tsung-Ying [10 ,13 ]
Chen, Kun-Chieh [10 ,14 ]
Li, Yao-Jen [1 ,5 ]
Hsu, Kuo-Hsuan [10 ]
Tsai, Chi-Rne [11 ,15 ]
Chen, Chih-Yi [16 ,17 ]
Hsu, Chung-Ping [6 ,12 ]
Hsia, Jiun-Yi [12 ]
Chuang, Cheng-Yen [10 ,12 ]
Tsai, Ying-Huang [19 ]
Chen, Kuan-Yu [7 ,8 ]
Huang, Ming-Shyan [20 ]
Su, Wu-Chou [21 ,22 ]
Chen, Yuh-Min [6 ,9 ]
Hsiung, Chao A. [23 ]
Shen, Chen-Yang [2 ,3 ,4 ,18 ]
Chang, Gee-Chen [6 ,10 ,14 ,17 ]
Yang, Pan-Chyr [7 ,8 ]
Chen, Chien-Jen [1 ,5 ]
机构
[1] Acad Sinica, Genome Res Ctr, Taipei 11529, Taiwan
[2] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan
[3] Acad Sinica, Taiwan Biobank, Taipei 11529, Taiwan
[4] Acad Sinica, Life Sci Lib, Taipei 11529, Taiwan
[5] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10764, Taiwan
[6] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[8] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[9] Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[10] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung 40705, Taiwan
[11] Taichung Vet Gen Hosp, Dept Pediat, Taichung 40705, Taiwan
[12] Taichung Vet Gen Hosp, Div Thorac Surg, Dept Surg, Taichung 40705, Taiwan
[13] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung, Taiwan
[14] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan
[15] Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan
[16] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan
[17] Sch Med, Taichung, Taiwan
[18] China Med Univ, Grad Inst Environm Sci, Taichung, Taiwan
[19] Chang Gung Mem Hosp, Dept Pulm & Crit Care, Lincou, Taiwan
[20] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan
[21] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan
[22] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan
[23] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan
关键词
GROWTH-FACTOR RECEPTOR; TETRANUCLEOTIDE REPEAT POLYMORPHISM; BREAST-CANCER; CYP17; GENE; ER-ALPHA; EXPRESSION; BETA; CARCINOGENESIS; THERAPY; CELLS;
D O I
10.1158/1078-0432.CCR-10-2045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess whether polymorphisms of genes related to estrogen biosynthesis and metabolism are associated with EGFR mutations. Experimental Design: We studied 617 patients with lung adenocarcinoma, including 302 never-smoking women. On the basis of multiple candidate genes approach, the effects of polymorphisms of CYP17, CYP19A1, ER alpha, and COMT in association with the occurrence of EGFR mutations were evaluated using logistic regression analysis. Results: In female never-smokers, significant associations with EGFR L858R mutation were found for the tetranucleotide (TTTA)(n) repeats in CYP19A1 (odds ratio, 2.6; 95%CI, 1.2-5.7 for 1 or 2 alleles with (TTTA)(n) repeats > 7 compared with both alleles with (TTTA) n repeats <= 7), and the rs2234693 in ERa (OR, 2.1; 95% CI, 1.1-4.0 for C/T and C/C genotypes compared with T/T genotype). The C/C genotype (vs. T/T genotype) of ERa was significantly associated with EGFR L858R mutation (OR, 3.0; 95% CI, 1.1-8.1), in-frame deletion (OR, 2.9; 95% CI, 1.1-7.6) and other mutations (OR, 4.3; 95% CI, 1.3-14.0). The genotype of COMT rs4680 was significantly associated with EGFR L858R mutation in female and male never-smokers showing OR's (95% CI) of 1.8 (1.0-3.2) and 3.6 (1.1-11.3), respectively, for genotypes G/A and G/G compared with genotype A/A. The number of risk alleles of CYP17, CYP19A1, ERa, and COMT was associated with an increasing OR of EGFR L858R mutation in female never-smokers (P = 0.0002 for trend). Conclusions: The L858R mutation of EGFR is associated with polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res; 17(8); 2149-58. (C) 2011 AACR.
引用
收藏
页码:2149 / 2158
页数:10
相关论文
共 50 条
  • [21] 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
    Liu, Guixue
    Xu, Zhihan
    Ge, Yingqian
    Jiang, Beibei
    Groen, Harry
    Vliegenthart, Rozemarijn
    Xie, Xueqian
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1212 - +
  • [22] Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
    He, Cheng
    He, Yifu
    Luo, Huiqin
    Zhang, Ming
    Wu, Jing
    He, Xiaofang
    Fu, Yuying
    Chen, Wenju
    Zou, Jinkun
    ONCOLOGY LETTERS, 2019, 18 (01) : 792 - 803
  • [23] Synchronous Double Primary Lung Adenocarcinomas With EGFR L858R Point Mutation and MET Exon 14 Skipping Mutation
    Ando, Seijitsu
    Futami, Shinji
    Azuma, Koji
    Nishimatsu, Kanako
    Shirasaka, Takuma
    Minami, Seigo
    JOURNAL OF MEDICAL CASES, 2024, 15 (08) : 153 - 158
  • [24] Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation
    Lin, Chou-Han
    Ho, Chao-Chi
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [25] L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report
    Xiang, Xianhong
    Yu, Jianxing
    Lai, Yingrong
    He, Weiling
    Li, Shuhua
    Wang, Liantang
    Ke, Zunfu
    ONCOLOGY LETTERS, 2015, 10 (03) : 1293 - 1296
  • [26] Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
    Yujie Cui
    Jinlong Liang
    Xiyun Kang
    Miaomiao Liu
    Qi Zhang
    Hongzhen Zhang
    Investigational New Drugs, 2023, 41 : 787 - 790
  • [27] Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
    Cui, Yujie
    Liang, Jinlong
    Kang, Xiyun
    Liu, Miaomiao
    Zhang, Qi
    Zhang, Hongzhen
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 787 - 790
  • [28] Lung adenocarcinoma harboring EGFR L858R mutation has increased invasive ability through up-regulation of CXCR4
    Chang, Tzu-Hua
    Yang, Hsiao-Yin
    Tsai, Meng-Feng
    Su, Kang-Yi
    Yang, Pan-Chyr
    Shih, Jin-Yuan
    CANCER RESEARCH, 2011, 71
  • [29] The Performance of an L858R Mutation Specific EGFR Antibody in Non-Small Cell Lung Cancer Specimens
    Kyshtoobayeva, A.
    Bloom, K. J.
    MODERN PATHOLOGY, 2012, 25 : 480A - 481A
  • [30] Neoantigen screening identifies EGFR L858R mutation immunogenicity in 1862 Chinese NSCLC patients.
    Lin, Jin
    Chen, Yu
    Chen, Gang
    Jun, Liu
    Hao, Shiguang
    Xiong, Jia-ni
    Lan, Bin
    Xu, Yaping
    Guan, Yan-Fang
    Guo, Zengqing
    Chen, Lin
    Chen, Li-zhu
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)